TENX
Company Description
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49,286 | 49,286 |
| Net Income | (52.60M) | (17.60M) | (7.71M) | (11.05M) | (32.47M) | (9.85M) | (8.39M) | (6.81M) | (8.84M) | (43.92M) | (14.08M) | (14.08M) |
| EPS | -1.34 | -1.15 | -31.09 | -600.80 | -2524.80 | -2125.38 | -26.60 | -7359.14 | -10022.32 | -624.82 | -200.61 | -16038.51 |
| Free Cash Flow | (35.80M) | (14.81M) | (5.90M) | (12.02M) | (10.86M) | (9.28M) | (7.56M) | (5.51M) | (12.15M) | (15.87M) | (9.86M) | (9.41M) |
| FCF / Share | -0.91 | -0.97 | -23.81 | -653.32 | -844.59 | -2001.37 | -1952.41 | -6018.64 | -13273.28 | -18079.94 | -11228.30 | -10715.96 |
| Operating CF | (35.80M) | (14.81M) | (5.90M) | (12.01M) | (10.86M) | (9.27M) | (7.56M) | (5.50M) | (12.14M) | (15.87M) | (9.75M) | (9.26M) |
| Total Assets | 104.23M | 96.69M | 11.68M | 3.40M | 5.99M | 6.87M | 6.37M | 13.34M | 9.89M | 23.34M | 72.99M | 86.19M |
| Total Debt | 0 | 0 | 500,903 | 807,891 | 290,781 | 305,036 | 171,732 | 0 | 0 | 0 | 100,160 | 151,255 |
| Cash & Equiv | 97.56M | 94.85M | 9.79M | 2.12M | 5.58M | 6.25M | 4.91M | 12.37M | 1.60M | 10.00M | 3.66M | 9.92M |
| Book Value | 97.07M | 91.99M | 8.10M | 1.49M | 4.24M | 4.63M | 3.77M | 11.77M | 8.88M | 17.14M | 60.42M | 75.36M |
| Return on Equity | -0.54 | -0.19 | -0.95 | -7.40 | -7.65 | -2.13 | -2.23 | -0.58 | -1.00 | -2.56 | -0.23 | -0.19 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (15.72M) | (15.54M) | (15.80M) | (10.85M) | (10.41M) | (6.27M) | (3.96M) | (3.58M) | (3.80M) | (3.23M) | (1.97M) | (1.11M) |
| EPS | -0.35 | -0.39 | -0.40 | -0.27 | -0.28 | -0.18 | -0.19 | -1.83 | -3.12 | -10.81 | -6.61 | -4.00 |
| Free Cash Flow | (9.31M) | (13.41M) | (9.15M) | (6.26M) | (6.97M) | (3.53M) | (3.09M) | (3.03M) | (5.17M) | (1.17M) | (2.08M) | (922,966) |
| FCF / Share | -0.21 | -0.34 | -0.23 | -0.16 | -0.19 | -0.23 | -0.15 | -1.55 | -4.24 | -4.73 | -6.98 | -3.34 |
| Operating CF | (9.31M) | (13.41M) | (9.15M) | (6.26M) | (6.97M) | (3.53M) | (3.09M) | (3.03M) | (5.17M) | (1.17M) | (2.08M) | (922,966) |
| Total Assets | 123.18M | 104.23M | 102.81M | 105.86M | 112.06M | 96.69M | 99.78M | 10.62M | 14.46M | 11.68M | 11.89M | 14.05M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 278,802 | 413,174 | 500,903 | 174,466 | 345,749 |
| Cash & Equiv | 118.75M | 97.56M | 99.37M | 105.46M | 111.45M | 94.85M | 98.31M | 9.38M | 12.55M | 9.79M | 11.14M | 13.39M |
| Book Value | 114.69M | 97.07M | 96.21M | 103.33M | 109.29M | 91.99M | 97.22M | 8.88M | 12.43M | 8.10M | 11.29M | 13.22M |
| Return on Equity | -0.14 | -0.16 | -0.16 | -0.10 | -0.10 | -0.07 | -0.04 | -0.40 | -0.31 | -0.40 | -0.17 | -0.08 |
